|
Video: What is a Stock Split?
|
|
Checkpoint Therapeutics is a clinical-stage immunotherapy and targeted oncology company focused on the acquisition, development and commercialization of treatments for patients with solid tumor cancers. Co. is evaluating its primary antibody product candidate, cosibelimab, an anti-programmed death-ligand 1 antibody, in an ongoing global, open-label, multicohort clinical trial in checkpoint therapy-naive patients with selected recurrent or metastatic cancers. Co. is also evaluating its main small-molecule, targeted anti-cancer agent, olafertinib, an epidermal growth factor receptor (EGFR) inhibitor, as a potential treatment for patients with EGFR mutation-positive non-small cell lung cancer. According to our CKPT split history records, Checkpoint Therapeutics has had 1 split. | |
|
Checkpoint Therapeutics (CKPT) has 1 split in our CKPT split history database. The split for CKPT took place on December 06, 2022. This was a 1 for 10 reverse split, meaning for each 10 shares of CKPT owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 100 share position following the split.
When a company such as Checkpoint Therapeutics conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the CKPT split history from start to finish, an original position size of 1000 shares would have turned into 100 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Checkpoint Therapeutics shares, starting with a $10,000 purchase of CKPT, presented on a split-history-adjusted basis factoring in the complete CKPT split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
06/28/2017 |
|
End date: |
04/16/2024 |
|
Start price/share: |
$100.00 |
|
End price/share: |
$1.69 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-98.31% |
|
Average Annual Total Return: |
-45.10% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$168.91 |
|
Years: |
6.81 |
|
|
|
Date |
Ratio |
12/06/2022 | 1 for 10 |
|
|